138668-55-0

Upstream product

• 132195-43-8 3-(2,6-dichloro-3-fluoro-4-methyl-5-pyridinyl)-3-oxopropionic acid ethyl ester 
• 132195-45-0 2-(ethoxymethylene)-3-(2,6-dichloro-3-fluoro-4-methyl-5-pyridinyl)-3-oxopropionic acid ethyl ester 
• 132195-59-6 7-chloro-6-fluoro-5-phenyl-1-(2,4-difluorophenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid ethyl ester 
• 132195-58-5 (Z)-2-(2,6-Dichloro-5-fluoro-4-methyl-pyridine-3-carbonyl)-3-(2,4-difluoro-phenylamino)-acrylic acid ethyl ester 
• 149366-73-4 2,6-Dichloro-5-fluoro-4-methyl-nicotinoyl chloride 
• 132195-42-7 2,6-dichloro-5-fluoro-4-methylnicotinic Acid 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 367-25-9 2,4-difluorophenylamine 

Relevant academic research and scientific papers

Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids

A series of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids have been prepared and tested for their in vitro and in vivo antibacterial activities.The 5-methyl group gave better in vitro activity with the 1-cyclopropyl appendage, but poorer activity with the 1-tert-butyl moiety.With the 1-(2,4-difluorophenyl) substitution, the influence of the 7-cycloalkylamino group was determinant: a (3S)-3-aminopyrrolidine was shown to enhance greatly the in vitro and in vivo activity of the 5-methyl derivative.Compound 33 (BMY 43748) was selec ted as a promising candidate for an improved therapeutic agent.